Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc ICOTF


Primary Symbol: T.MSCL Alternate Symbol(s):  MSCLF

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).


TSX:MSCL - Post by User

Comment by Alba1314on Jun 21, 2018 9:32am
88 Views
Post# 28204555

RE:RE:RE:Targeted Markets iCo-007 - Diabetes-Related Blindness ~$3B+.

RE:RE:RE:Targeted Markets iCo-007 - Diabetes-Related Blindness ~$3B+.Not bashing the stock, as I own 100K shares, but Andrew Rae buying $20,000 worth of shares, to me, means nothing. If he really knew something, then $20K is chump change. Wouldnt you be remortgaging your home if you "knew something"?

The $32 milliom is still a ways off and is still only a possibility though I agree it can't be dismissed. But there's still a few more years of studies to be completeted. Correct me if I'm wrong, but if the drug doesnt go to market, then the $32M never happens.

Completing recruitment for the oral Amp B study is a plus but we still need to see more positive results. 

I dont see this moving that much higher. Too much speculation at this point. Would love to be wrong!
<< Previous
Bullboard Posts
Next >>